文献速递前列腺癌

优化根治性前列腺切除术后病理性淋巴结阳性前列腺癌男性的抗雄激素治疗使用:术后PSA动力学的重要性

Optimizing anti-androgen treatment use among men with pathologic lymph-node positive prostate cancer treated with radical prostatectomy: the importance of postoperative PSA kinetics.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2022-07-06

在297例根治性前列腺切除术后病理性淋巴结阳性(pN1)前列腺癌患者中,基于术后PSA最低值和生化失败时间构建3个风险组,发现中危和高危组立即雄激素剥夺治疗(iADT)较观察±延迟ADT降低转移风险,低危组无获益。

要点

  • 回归树基于PSA最低值和生化失败时间分出3个风险组,Harrell C指数0.79。
  • 中危组10年无转移生存iADT 80.6% vs 观察±延迟ADT 53.5%(Log-rank p=0.016)。
  • 高危组10年无转移生存iADT 41.5% vs 观察±延迟ADT 0%(Log-rank p=0.015)。

核心结论

  • 根治性前列腺切除术后早期PSA动力学可能为指导ADT启动时机提供有价值信息,可能减少pN1前列腺癌男性的过度治疗和治疗不足。

研究设计与样本

  • 在2002年至2018年间于本机构前瞻性维护的癌症数据登记处识别297例接受根治性前列腺切除术和扩大盆腔淋巴结清扫(ePLND)的pN1前列腺癌患者。
  • 术后患者接受立即雄激素剥夺治疗(iADT,术后≤6个月内给药)或观察±延迟ADT(dADT,术后>6个月给药)。
  • 主要结局为转移,采用回归树分析基于术后肿瘤特征和PSA动力学分层为新风险组,并在各风险组内分别用多变量Cox回归分析iADT与观察±dADT对转移、癌症特异性死亡和总死亡的影响。

主要发现

  • 中位随访6.1年(IQR 3.2-9.0)。
  • 回归树分析将患者分为3个新风险组(Harrell C指数0.79):1组(低危)为生化复发时间>6个月(n=115);2组(中危)为生化失败≤6个月且术后PSA最低值<1.05 ng/mL(n=125);3组(高危)为生化失败≤6个月且术后PSA最低值≥1.05 ng/mL(n=57)。
  • 各风险组10年无转移生存率iADT vs 观察±dADT:1组100% vs 95.4%(Log-rank p=0.738),2组80.6% vs 53.5%(Log-rank p=0.016),3组41.5% vs 0%(Log-rank p=0.015)。
  • 调整Cox回归分析证实iADT在2组(p=0.029)和3组(p=0.008)降低转移,1组无获益(p=0.918);癌症特异性和总死亡结果类似。

关键数值与推荐

  • 风险组1(低危):生化复发时间>6个月,n=115,10年无转移生存iADT 100% vs 观察±dADT 95.4%(Log-rank p=0.738)。
  • 风险组2(中危):生化失败≤6个月且术后PSA最低值<1.05 ng/mL,n=125,10年无转移生存iADT 80.6% vs 观察±dADT 53.5%(Log-rank p=0.016)。
  • 风险组3(高危):生化失败≤6个月且术后PSA最低值≥1.05 ng/mL,n=57,10年无转移生存iADT 41.5% vs 观察±dADT 0%(Log-rank p=0.015)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Optimal postsurgical management of prostate cancer (PCa) patients with nodal metastasis at the time of radical prostatectomy remains unclear. We sought to examine the role of postoperative PSA kinetics and pathologic tumor characteristics in guiding additional hormonal therapy use in pN1 men. METHODS: In total, 297 pN1 PCa patients treated with radical prostatectomy and ePLND between 2002 and 2018 were identified within our prospectively maintained institutional cancer data-registry. Following surgery, these patients were managed with either immediate androgen deprivation therapy (iADT) or observation with deferred ADT (dADT). The former was defined as ADT given within ≤6 months of surgery and the latter as >6 months. The primary outcome was metastasis. Regression-tree analysis was used to stratify patients into novel risk-groups based on post-prostatectomy tumor characteristics and PSA kinetics and the corresponding metastasis risk. Multivariable Cox regression analyses tested the impact of iADT versus observation ± dADT on metastasis, cancer-specific mortality, and overall mortality within each risk-group separately. RESULTS: The median follow-up was 6.1 years (IQR 3.2-9.0). Regression-tree analysis stratified patients into 3 novel risk-groups (Harrell's C-index 0.79) based on PSA-nadir and time to biochemical failure: group 1 (low-risk) included patients with time to biochemical recurrence >6 months (n = 115), while groups 2 and 3 included patients with biochemical failure within ≤6 months with a postoperative PSA-nadir <1.05 ng/mL (group 2 [intermediate-risk], n = 125) or ≥1.05 ng/mL (group 3 [high-risk], n = 57), respectively. No other patient or tumor characteristics were significant for risk stratification. Within each risk-group, the 10-year metastasis-free survival rates with iADT versus observation ± dADT use were: group 1, 100% versus 95.4% (Log-rank p = 0.738), group 2, 80.6% versus 53.5% (Log-rank p = 0.016), and group 3, 41.5% versus 0% (Log-rank p = 0.015), respectively. Adjusted Cox regression analyses confirmed the benefit of iADT utilization in reducing metastasis in group 2 (p = 0.029) and group 3 (p = 0.008) patients, with no benefit for group 1 patients (p = 0.918). Similar results were noted for cancer-specific and overall mortality. CONCLUSIONS: Following radical prostatectomy, early postoperative PSA kinetics may provide valuable information for guiding the timing of ADT initiation-this may reduce over- and undertreatment of pN1 PCa men.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Sood A, Zhang LT, Keeley J, et al. Optimizing anti-androgen treatment use among men with pathologic lymph-node positive prostate cancer treated with radical prostatectomy: the importance of postoperative PSA kinetics. Prostate Cancer Prostatic Dis. 2022. PMID: 35794359. doi:10.1038/s41391-022-00572-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。